| Literature DB >> 26391127 |
Francesco Cavallin1, Eleonora Pinto2, Luca M Saadeh3, Rita Alfieri4, Matteo Cagol5, Carlo Castoro6, Marco Scarpa7.
Abstract
BACKGROUND: Oesophagectomy for cancer could be safe and worthwhile in selected older patients, but less is known about the effect of oesophagectomy on perceived quality of life of such delicate class of cancer patients. The aim of this study was to evaluate the impact of oesophagectomy for cancer in elderly patients in term of health-related quality of life.Entities:
Mesh:
Year: 2015 PMID: 26391127 PMCID: PMC4578681 DOI: 10.1186/s12885-015-1647-5
Source DB: PubMed Journal: BMC Cancer ISSN: 1471-2407 Impact factor: 4.430
Comparison between patients who did and did not fill the questionnaires
| Patients who did not fill the questionnaires | Patients who filled the questionnaires | ||
|---|---|---|---|
| N | 74 | 109 | - |
| Gender Male: Female | 60:14 | 92:17 | 0.55 |
| Age (years)a | 63 (54–70) | 61 (53–68) | 0.35 |
| Histotype:b | 0.75 | ||
| Adenocarcinoma | 49 (66.2) | 75 (69.4) | |
| Squamous cell carcinoma | 25 (33.8) | 33 (30.6) | |
| Tumour site: | 0.08 | ||
| Cervical oesophagus | 4 (5.4) | 6 (5.5) | |
| Thoracic oesophagus | 19 (26.7) | 14 (12.8) | |
| Oesophago-gastric junction | 51 (68.9) | 89 (81.7) | |
| Neoadjuvant therapy: yes | 51 (68.9) | 90 (82.6) | 0.05 |
| Hospital stay (days)a | 14 (13–20) | 19 (17–24) | <0.0001 |
| Pathological stagec | 0.16 | ||
| 0 | 8 (10.8) | 25 (23.0) | |
| I | 18 (24.3) | 19 (17.4) | |
| II | 18 (24.3) | 24 (22.0) | |
| III | 29 (39.2) | 36 (33.0) | |
| IV | 1 (1.4) | 5 (4.6) | |
| Post-operative morbidity | 22 (29.7) | 29 (26.6) | 0.74 |
| Type of post-operative complications: | |||
| Anastomotic leak | 6 | 8 | |
| Pulmonary | 4 | 17 | |
| Cardiac | 7 | 9 | |
| Dysphonia | 0 | 3 | |
| Urinary | 3 | 4 | |
| Bleeding | 3 | 1 | |
| Sepsis | 0 | 1 | |
| Chylothorax | 1 | 0 | |
| Diaframmatic hernia | 0 | 1 | |
| Deep venous thrombosis | 0 | 1 | |
| Pyloric stenosis | 1 | 0 | - |
Data expressed as n (%) or amedian (IQR)
bOther histotype in one patient
cPathological stage is ypstage for patients who received neoadjuvant therapy and pstage for patients who did not
Patients who filled the questionnaires: younger vs. older patients
| Age < 70 | Age > =70 | ||
|---|---|---|---|
| N | 86 | 23 | - |
| Gender Male: Female | 73:13 | 19:4 | 0.75 |
| Age (years)a | 58 (51–64) | 75 (72–80) | <0.0001 |
| Histotype:b | 0.14 | ||
| Adenocarcinoma | 62 (72.9) | 13 (56.5) | |
| Squamous cell carcinoma | 23 (27.1) | 10 (43.5) | |
| Tumour site: | 0.42 | ||
| Cervical oesophagus | 6 (7.0) | 0 | |
| Thoracic oesophagus | 10 (11.6) | 4 (17.4) | |
| Oesophago-gastric junction | 70 (81.4) | 19 (82.6) | |
| Prognostic nutritional indexa | 49.0 (46.5–52.0) | 48.2 (44.4–50.7) | 0.39 |
| Charlson Comorbidity Indexa | 2 (2–3) | 3 (2–3) | 0.09 |
| Age related Charlson Comorbidity Indexac | 3 (2–4) | 5 (5–6) | <0.0001 |
| Neoadjuvant therapy | 75 (87.2) | 15 (65.2) | 0.03 |
| Type of neoadjuvant therapy: | - | ||
| Chemotherapy | 24 (32.0) | 5 (33.3) | |
| Radiotherapy | 1 (1.3) | 0 | |
| Chemo-radiotherapy | 50 (66.7) | 10 (66.7) | |
| Hospital stay (days)a | 19 (16–24) | 23 (18–30) | 0.04 |
| Pathological staged | 0.07 | ||
| 0 | 23 (26.7) | 2 (8.7) | |
| I | 16 (18.6) | 4 (13.0) | |
| II | 14 (16.3) | 10 (43.5) | |
| III | 29 (33.7) | 7 (30.4) | |
| IV | 4 (4.7) | 1 (4.4) | |
| Post-operative morbidity | 20 (23.3) | 9 (39.1) | 0.18 |
Data expressed as n (%) or amedian (IQR)
bOther histotype in one patient
cComparison biased due to age penalization in score calculation
dPathological stage is ypstage for patients who received neoadjuvant therapy and pstage for patients who did not
Health-related quality of life in older patients (age > =70) compared with younger patients (age < 70), at admission, at discharge and at 3 months after surgery, without a significant time interaction
| EORTC aspect | MD (95 % C.I.) | |
|---|---|---|
| C30 global quality of life | 4.4 (−5.2, 14.1) | n.a. |
| C30 physical function | −3.1 (−10.9, 4.8) | n.a. |
| C30 role function | 9.3 (−4.3, 23.0) | n.a. |
| C30 emotional function | −0.5 (−10.6, 9.6) | n.a. |
| C30 cognitive function | −5.9 (−13.5, 1.7) | n.a. |
| C30 social function | −2.3 (−14.5, 9.8) | n.a. |
| C30 fatigue | 3.2 (−6.7, 13.1) | n.a. |
| C30 dyspnoea | −3.6 (−13.5, 6.3) | n.a. |
| OES18 dysphagia | −2.8 (−14.2, 8.6) | n.a. |
Mean score difference (MDs) were assessed with linear mixed-effect models and adjusted for time
Charlson Comorbidity Index, neoadjuvant therapy, tumour stage, gender, histology, tumour site and complications. All these values did not show a significant time interaction term, i.e. the difference persisted over time. Any MD ≥ 10 was considered clinically significant and tested for statistical significance (n.a., not applicable, if MD < 10)
Differences in health-related quality between older patients (age > =70) and younger patients (age < 70), at admission, at discharge and at 3 months after surgery, with significant time interaction
| OES18 aspects | Admission | Discharge | 3 months after surgery | |||
|---|---|---|---|---|---|---|
| MD (95 % C.I.) | MD (95 % C.I.) | MD (95 % C.I.) | ||||
| Trouble swallowing saliva | 17.4 (3.6, 31.2) | 0.01 | −7.5 (−20.7, 5.7) | n.a. | 0,2 (−18.9, 19.3) | n.a. |
| Choking when swallowing | 13.8 (5.8, 21.8) | 0.0008 | −0.5 (−7.9, 6.9) | n.a. | −2.5 (−13.6, 8.6) | n.a. |
| Eating | 20.1 (7.4, 32.8) | 0.002 | 2.4 (−9.5, 14.3) | n.a. | 0.5 (−17.2, 18.2) | n.a. |
Mean score difference (MDs) were assessed with linear mixed-effect models and adjusted for time
Charlson Comorbidity Index, neoadjuvant therapy, tumour stage, gender, histology, tumour site and complications. Any MD ≥ 10 was considered clinically significant and tested for statistical significance (n.a., not applicable, if MD < 10)
Fig. 1HRQL in older (black) and younger (grey) patients at admission, at discharge and at 3 months after surgery. Legend: Estimates of selected EORTC aspects (with 95 % Confidence Intervals) as calculated by linear mixed-effect models, adjusting for time, Charlson Comorbidity Index, neoadjuvant therapy, tumour stage, gender, histology, tumour site and complications.. A significant group-by-time interaction (p < 0.01) in OES18 trouble swallowing saliva, OES18 choking when swallowing and OES18 eating suggested more problems in older patients than younger ones at admission, but not at discharge and at 3 months after surgery. C30 global quality of life did not change over time (p = 0.57)